gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Further Improvements by Innovative Taxane-Containing Cytostatic Regimens for the Treatment of Early Breast Cancer - Evaluated by the German SUCCESS-Study

Meeting Abstract

  • corresponding author presenting/speaker Harald Sommer - I. Univ-Frauenklinik, Klinikum der LMU, München, Deutschland
  • M W Beckmann - Universitätsfrauenklinik, Erlangen
  • W. Lichtenegger - Charité-Frauenklinik, Berlin
  • W. Janni - I. Univ-Frauenklinik, Klinikum der LMU, München
  • B. Rack - I. Univ-Frauenklinik, Klinikum der LMU, München
  • M. Heinrigs - I. Univ-Frauenklinik, Klinikum der LMU, München
  • E. Genss - I. Univ-Frauenklinik, Klinikum der LMU, München
  • U. Söling - Gemeinschaftspraxis Siehl/Söling, Kassel
  • H. Tesch - Praxis Tesch, Frankfurt
  • D.M. Zahm - Wald-Klinikum, Gera
  • A. Schneider - Frauenklinik Freie Universität, Berlin
  • K. Friese - I. Univ-Frauenklinik, Klinikum der LMU, München

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocOP003

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dkk2006/06dkk113.shtml

Veröffentlicht: 20. März 2006

© 2006 Sommer et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Background: In several randomized trials, taxane containing regimens have demonstrated superiority compared to mere anthracycline containing schedules for the adjuvant treatment of early breast cancer. Given an array of novel drugs, continuing improvements in the adjuvant setting may further reduce breast cancer mortality in future.

Methods: The SUCCESS-Study is an open-label, multicenter, 2x2 factorial design, randomized controlled, Phase III study comparing the disease free survival after randomisation in patients treated with 3 cycles of Epirubicin-Fluorouracil-Cyclophosphamide(FEC)-chemotherapy, followed by 3 cycles of Docetaxel(D)-chemotherapy versus 3 cycles of Epirubicin-Fluorouracil-Cyclophosphamide(FEC), followed by 3 cycles of Gemcitabine-Docetaxel(DG)-chemotherapy, and to compare the disease free survival after randomisation in patients treated with 2 years of Zoledronate versus 5 years of Zoledronate in patients with early primary breast cancer.

Results: The SUCCESS-Study (n= 3.658) was opened for active recruitment on September 15th, 2005. At this point of time 160 treatment centers have been approved by local and national ethical boards for active participation. Patients will be required to have histopathological proof of axillary lymph node metastases (pN1-3) or high risk node negative, defined as: ‘pT³2 or histopathological grade 3, or age £ 35 or negative hormone receptor’, but are not allowed to have evidence of distant disease. The status of the patient recruitment and the incidence of serious adverse events will be presented at the meeting.

Conclusion: The SUCCESS-Study (www.success-studie.de) will provide major contributions to resolve current controversies on the role of taxane combinations and of bisphosphonates in the adjuvant treatment of early breast cancer.